Nasus Pharma Taps Teva Veteran O'Grady as CEO to Drive NS002 Commercialization
Event summary
- Nasus Pharma appoints Brendan P. O'Grady as CEO effective July 27, 2026.
- O'Grady succeeds Dan Teleman with a focus on commercializing NS002 for anaphylaxis treatment.
- NS002 pivotal trial expected in Q4 2026 with topline data readout in Q1 2027.
- O'Grady brings 35 years of pharmaceutical experience, including leadership roles at Teva and Assertio Holdings.
The big picture
Nasus Pharma's appointment of O'Grady signals a strategic pivot toward commercialization, aligning with broader industry trends where clinical-stage biopharmaceutical companies increasingly prioritize go-to-market execution. The move comes as Nasus prepares for pivotal trials and topline data readouts, reflecting the growing emphasis on pre-commercial planning in the competitive intranasal therapies space.
What we're watching
- Commercialization Strategy
- How O'Grady's experience in payors and reimbursement will shape NS002's market entry.
- Pipeline Execution
- Whether Nasus can sustain momentum across its intranasal technology platform beyond NS002.
- Market Differentiation
- The pace at which NS002 gains traction against injectable alternatives in the $2 billion anaphylaxis market.